LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Summary Public Assessment Report

Bimtim
(bimatoprost, timolol)

SE/H/2496/01/DC

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se

Summary Public Assessment Report

Bimtim
bimatoprost, timolol, timolol maleate

Eye drops, solution in single-dose container, 0,3 mg/ml + 5 mg/ml

This is a summary of the public assessment report (PAR) for Bimtim. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Bimtim and what is it used for?

The product is a 'hybrid medicine'. This means that it is similar to a reference medicine containing the same active substance.

The reference medicine for the product is Ganfort.

The company has provided additional own data to demonstrate therapeutic equivalence between the product and the reference medicine.

The product is used to treat high pressure in the eye in adults, including the elderly. This high pressure can lead to glaucoma.

How does Bimtim work?

Bimtim contains two different active substances (bimatoprost and timolol) that both reduce pressure in the eye. Bimatoprost belongs to a group of medicines called prostamides, a prostaglandin analogue. Timolol belongs to a group of medicines called beta-blockers.

Your eye contains a clear, watery liquid that feeds the inside of the eye. Liquid is constantly being drained out of the eye and new liquid is made to replace this. If the liquid cannot drain out quickly enough, the pressure inside the eye builds up and could eventually damage your sight (an illness called glaucoma). Bimtim works by reducing the production of liquid and also increasing the amount of liquid that is drained. This reduces the pressure inside the eye.

How is Bimtim used?

The pharmaceutical form is eye drops, solution, single-dose container for ocular use.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Bimtim have been shown in studies?

Because the product is a hybrid application and is considered to be therapeutically equivalent to the reference product Ganfort, the benefits and risks are taken as being the same as those of the reference medicine.

What are the possible side effects from Bimtim?

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Bimtim approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered to be similar to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Ganfort, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Bimtim?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Bimtim

The full PAR for Bimtim can be found on the following website: MRI - Home. For more information about treatment with Bimtim, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2025-04.